Podcasts about cancer screenings

In this podcast episode, Paul Limburg, MD, MPH, discusses the movement from academics to industry, developments in colorectal cancer screening tools and more. •    Intro 1:11 •    Paul Limburg, MD, MPH  1:17 •    How did your early influences and childhood years lead you to become interested in gastroenterology and the career you have today?  1:34 •    Who were your early inspirations?  2:14 •    How did you transition from a career in academics and sciences to a life on the commercial side? 3:34 •    How did your role at Exact Sciences come about? 5:58 •    Was it a hard decision to take a new position? 7:47 •    Chey and Limburg on the joy of advancing science and innovation. 9:03 •    Were there any cultural differences that shocked you about the ways work is done in your previous and current positions? 10:10  •    Do you see Exact outsourcing scientific research as the company grows? 12:12 •    What does a typical day look like for you at Exact? […] What are you responsible of as the leading physician? 13:28 •    From a product standpoint, what is ahead on the roadmap for Exact Sciences? […] What are you most excited about regarding next-generation multi-target stool testing and its impact? 15:14 •    How do you respond to gastroenterologists' skepticism and concerns surrounding stool-based screening? 21:15 •    What about addressing the concerns surrounding how we can ensure patients with a positive FIT test go in for a colonoscopy? 23:22 •    How much of an issue are language barriers when it comes to screening tools? 28:11 •    Can you talk about how Exact Sciences are using AI and the evolution of the microbiome internally or in product development? 29:42 •    Do you see a future for stool-based testing in between/in combination with colonoscopies? 32:59 •    Have you noticed differences in sensitivity and specificity based on age? 34:07 •    What are your thoughts on making these tools available in a direct-to-consumer offering? […] How do you make these screening tools more readily available while weighing the usage risks? 35:08 •    What is the rate of patients who have a positive stool-based test getting a colonoscopy? 38:44 •    If you were talking to a GI fellow deciding to make the jump to industry, what do you tell them? 41:58 •    Thank you, Paul 44:55 •    Thanks for listening 45:21 Paul J. Limburg, MD, MPH, is chief medical officer for screening at Exact Sciences and emeritus professor of Medicine at Mayo Clinic.     We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Dr. Limburg, follow @limburg_paul and @ExactSciences on X. Disclosures: Chey and Berry report no relevant financial disclosures. Limburg reports he is an employee of Exact Sciences.

A recent report by the Canadian Cancer Statistics Advisory Committee found that after more than three decades of steady decline, cases of cervical cancer have plateaued in the past 20 years. In an effort to make screening less daunting, the Canadian Cancer Society is pushing for all provinces and territories to replace the traditional pap smear examination with the human papillomavirus (HPV) test. So far, only four provinces have made the switch.But the switch is just a piece of the puzzle. Access to screening, education on reproductive health, and destigmatizing testing all play a role in bringing down cases of cervical cancer - which Canada committed to eliminate by 2040.Host Maria Kestane speaks to Dr. Lucy Gilbert, director of the McGill University Gynecologic Oncology service, and chair of oncology for McGill University's Gerald Bronfman Department of Oncology to discuss the risks related with lack of access to proper screenings, and how Health Canada needs to keep health education top of mind if they want to meet its 2040 goal. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Full article: Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT How should radiologists handle suspected infectious or inflammatory findings on lung cancer screening CT? Brittany Miles, MD, talks with Randall Rosenblatt, MD, on the implications of Lung-RADS v2022 category 0 in this setting, based on the recent AJR article by Arora et al.

Bowel Cancer NZ's new report lays bare the realities of 350 people under 50 living with the disease. It's the second deadliest cancer in New Zealand, and the leading cause of cancer death among people under the age of 50. Every year around 3,300 New Zealanders are diagnosed and 1,200 die from the disease, despite it having a cure rate of over 90% when caught early. The Never Too Young report found more than half of those surveyed didn't know the symptoms prior to diagnosis, and many faced delays in diagnosis. Bowel Cancer NZ Chief Executive Peter Huskinson told Kerre Woodham if the screening age was lowered to 45, it would go a long way to catch the majority of people with early onset bowel cancer. He says that way they'd be caught by the screening, rather than waiting for symptoms to develop. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Host: Jasmine T. Kency, M.D., Associate Professor of Internal Medicine and Pediatrics at the University of Mississippi Medical Center.Guest(s): Priyanka Senthil, CEO of American Lung Cancer Screening Initiative and Sam Schwartz, National Director of American Lung Cancer Screening InitiativeTopic: Lung cancer screenings and the upcoming Jackson Stronger Together Community Health FairEmail the show: remedy@mpbonline.org. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

Dr. Caoimhe Hartley, GP with a specialist interest in Women's Health

Dr. Peter Michalos: Early Cancer Screening Can Save Your Life (7 min) Learn more about your ad choices. Visit megaphone.fm/adchoices

Broadcast from KSQD, Santa Cruz on 11-06-2025:>/p> Dr. Dawn interviews Cindy Jackonette and Dr. Michael Alexander about a fundraiser for pancreatic cancer awareness on November 15th at Bargetto Winery from 2-5pm, supporting the Santa Cruz Cancer Benefit Group. Dr. Alexander explains pancreatic cancer has only 10-15% five-year survival rates and is difficult to screen for. Screening involves complex endoscopy procedures examining pancreatic ducts, CT scans and biomarker scans. The disease represents 3% of cancer cases but 8% of deaths. Immune checkpoint inhibitors show limited success except in Lynch syndrome patients with DNA repair defects. The Santa Cruz Cancer Benefit Group donates annually to local cancer organizations and is all volunteer-run with minimal overhead. An emailer asks when her 56-year-old half-African American son should get colon cancer screening given his father and uncle both had the disease. Dr. Dawn explains African Americans have increased risk and recommends immediate colonoscopy despite the ideal screening window being 10 years ago. She emphasizes identifying whether he produces polyps, which would require surveillance every 3-5 years. Unlike pancreatic cancer, colon cancer is highly curable when detected early, with death rates dropping 30-40% since colonoscopies became standard in the mid-1990s. She recommends preventive measures including daily 200mg ibuprofen (if no ulcer history) and a high-fiber diet rich in colorful vegetables containing antioxidants that reduce oxidative stress and DNA damage from free radicals. An emailer from Israel asks about supporting his 38-year-old son's rectal adenocarcinoma treatment. Dr. Dawn recommends nutritional strategies including juicing 10 different fruits and vegetables daily, 20mg melatonin for synergy with chemotherapy, vitamin D supplementation, and L-glutamine as primary food for bowel healing and lymphocyte function. She suggests DHA fish oil to enhance chemotherapy effectiveness, green tea for oncogene inhibition, astragalus herb to increase phagocytic activity and natural killer cells, and rotating water-extracted mushroom formulas with beta-glucans, particularly maitake and shitake. Glutamine also protects mucous membranes from radiation burns. Dr. Dawn discusses alarming cancer rate increases among young adults in Corn Belt states including Iowa, Nebraska, Illinois, Minnesota, Indiana, and Kansas. Since 2015, these states show 5% higher cancer rates for ages 15-49 compared to national averages, with particularly elevated kidney and skin cancer rates. Young women face 66% higher skin cancer risk than peers in other states. . Governor Kim Reynolds invested $1 million for research while Bayer's attempt to shield Roundup from lawsuits failed. Dr. Dawn notes Roundup now contains diquat after removing glyphosate. It has taken decades to accumulate evidence of glyphosates harms, She warns that absence of evidence of Diquats being harmful isn't evidence of safety and that Ames testing suggests high mutation potential. An emailer shares a JAMA article on lithium for Alzheimer's disease. Dr. Dawn explains that calcium dysregulation through NMDA receptors plays an upstream role in Alzheimer's pathology. Lithium, a bipolar disorder treatment, can reset deranged calcium gates, inhibiting mitochondrial damage and tau protein production. She emphasizes tau protein as the true culprit in Alzheimer's while amyloid beta is more symptomatic. Correcting calcium homeostasis allows neuronal autophagy systems to clear waste more efficiently rather than being overwhelmed. She reports dramatic peanut allergy declines following 2017 pediatric recommendations for introducing peanuts at 4-6 months based on the LEAP study showing 81% reduction. Between 2017-2020, peanut allergies dropped from 0.79% to 0.45% of all children under 3, with overall food allergies declining 36%. Studies also show pregnant mothers eating peanuts reduces offspring allergy risk by promoting immune tolerance. We conclude with breakthrough wireless retinal implants for macular degeneration, where cameras on glasses convert images to near-infrared signals to retinal implants which stimulate surviving retinal neurons. The prototype allowed patients to improve by two lines on eye charts and perceive facial expressions and read smaller print.

Prop 50, the redistricting measure aimed at giving Democrats an edge in the midterms next year, is projected to pass. Poway voters appear likely to recall Councilmember Tony Blain over what critics say are unethical actions. UC San Diego Health is the only place in the country offering up a new test for testicular cancer.   What You Need To Know To Start Your Wednesday. 

Detecting Emerald Ash Borer Increasing Cancer Screenings in Kansas Having Healthy Calves   00:01:05 – Detecting Emerald Ash Borer: Shad Hufnagel, Kansas Forest Service forest health coordinator, begins today's show explaining emerald ash borer and how they have identified it in another county in Kansas. KansasForests.org   00:12:05 – Increasing Cancer Screenings in Kansas: The show continues with K-State's Jeff Wichman as he hosts Hope Krebill and Keren Denes-Collar on Sound Living as they discuss cancer screenings and how they hope to provide it to more people. Sound Living   00:23:05 – Having Healthy Calves: K-State dairy specialist Mike Brouk ends the show by saying how producers can boost their bottom line by keeping calves healthy as their value has increased.       Send comments, questions or requests for copies of past programs to ksrenews@ksu.edu.   Agriculture Today is a daily program featuring Kansas State University agricultural specialists and other experts examining ag issues facing Kansas and the nation. It is hosted by Shelby Varner and distributed to radio stations throughout Kansas and as a daily podcast.   K‑State Research and Extension is a short name for the Kansas State University Agricultural Experiment Station and Cooperative Extension Service, a program designed to generate and distribute useful knowledge for the well‑being of Kansans. Supported by county, state, federal and private funds, the program has county Extension offices, experiment fields, area Extension offices and regional research centers statewide. Its headquarters is on the K‑State campus in Manhattan

Dr. Matt Goldstein, CEO of jscreen, focuses on the importance and power of preventive genetic testing for reproductive carrier screening and hereditary cancer screening. All genetic tests include analysis to inform specific medical management plans and provide genetic counselors to explore options. Of particular interest is testing for the gene mutations that cause Tay-Sachs disease and helping families take proactive steps to effectively eliminate the disease in future generations. Matt explains, "So, jscreen is a nonprofit that focuses on providing access to education and high-touch support to individuals, families, and to clinicians in the area of preventive genetics and more specifically for reproductive carrier screening and hereditary cancer screening. "These types of tests actually have been around for a really long time with the advancement in genomic technology and our knowledge generally of genetics. The capabilities we have around these panels—what we can test for and what we can do with them—have grown tremendously over the last two decades. And so, what we're offering now is completely different than what you may have been offered five or 10 years ago." "What I will say is I think that this technology is the most powerful medical intervention that we have. Maybe second to vaccines, which we know obviously can have profound impacts on saving lives, preventive genetics, the ability to screen an individual or a couple or a family, and identify diseases that they may be at risk for, with things that you can do to prevent those diseases from happening or catch them early. That's the holy grail. That's the most amazing thing: being able to intervene."  #jscreen #GeneticTesting #TaySachsDisease #ReproductiveCarrierScreening #HereditaryCancerScreening  jscreen.org Download the transcript here

Dr. Matt Goldstein, CEO of jscreen, focuses on the importance and power of preventive genetic testing for reproductive carrier screening and hereditary cancer screening. All genetic tests include analysis to inform specific medical management plans and provide genetic counselors to explore options. Of particular interest is testing for the gene mutations that cause Tay-Sachs disease and helping families take proactive steps to effectively eliminate the disease in future generations. Matt explains, "So, jscreen is a nonprofit that focuses on providing access to education and high-touch support to individuals, families, and to clinicians in the area of preventive genetics and more specifically for reproductive carrier screening and hereditary cancer screening. "These types of tests actually have been around for a really long time with the advancement in genomic technology and our knowledge generally of genetics. The capabilities we have around these panels—what we can test for and what we can do with them—have grown tremendously over the last two decades. And so, what we're offering now is completely different than what you may have been offered five or 10 years ago." "What I will say is I think that this technology is the most powerful medical intervention that we have. Maybe second to vaccines, which we know obviously can have profound impacts on saving lives, preventive genetics, the ability to screen an individual or a couple or a family, and identify diseases that they may be at risk for, with things that you can do to prevent those diseases from happening or catch them early. That's the holy grail. That's the most amazing thing: being able to intervene."  #jscreen #GeneticTesting #TaySachsDisease #ReproductiveCarrierScreening #HereditaryCancerScreening  jscreen.org Listen to the podcast here

Dr. Faisal Khan explains what screening is available for lung cancer, who qualifies for a screening, and how often lung screening appointments should be made.

Kansas State University Extension and the University of Kansas Cancer Center have launched a partnership aimed at increasing awareness, access and participation in cancer screenings – especially in rural and underserved areas of the state. Hope Krebill, executive director of the Masonic Cancer Alliance, the outreach network of the University of Kansas Cancer Center, says the most common cancers in Kansas are the ones that we can prevent or screen for including prostate, breast, lung, colorectal and melanoma. Karin Denes-Collar, associate director and psychosocial services director for the Masonic Cancer Alliance, says that when we find a cancer early, it's much more likely to be treatable and survivable. Sound Living is a weekly public affairs program addressing issues related to families and consumers. It is hosted by Jeff Wichman. Each episode shares the expertise of K-State specialists in fields such as child nutrition, food safety, adult development and aging, youth development, family resource management, physical fitness and more. Send comments, questions or requests for copies of past programs to ksrenews@ksu.edu. K‑State Research and Extension is a short name for the Kansas State University Agricultural Experiment Station and Cooperative Extension Service, a program designed to generate and distribute useful knowledge for the well‑being of Kansans. Supported by county, state, federal and private funds, the program has county Extension offices, experiment fields, area Extension offices and regional research centers statewide. Its headquarters is on the K‑State campus in Manhattan.  

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

I recently had an ApoB test and am surprised that it isn't lower than it is.  Can you explain?I have an ascending thoracic aortic aneurysm.  How can I keep it from enlarging?Why are you against whole-body scans? Aren't they helpful?Can I take magnesium L-threonate while also taking magnesium glycinate?

Will Truheight vitamins really make your kids grow?Where can I learn more about complementary medicine and nutrition?The balls of my feet are sore along with my toes. Is this a vitamin deficiency?

Are you up to date on the latest screening techniques for cervical cancer? Credit available for this activity expires: 10/29/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/missed-and-risk-rewriting-cervical-cancer-screening-story-2025a1000t8c?ecd=bdc_podcast_libsyn_mscpedu

LEXINGTON, Ky. (October 30, 2025) – Kentucky continues to face one of the highest rates of lung cancer in the nation, but new advances at UK HealthCare are helping doctors shorten the time from diagnosis to life-saving treatment. Through the use of cutting-edge robotic systems, UK surgeons can now perform same-day biopsy and surgery for certain early-stage lung cancers — turning what was once weeks of waiting and anxiety into a single, coordinated procedure. Dr. Shari Meyerson, professor of surgery and division chief of thoracic surgery, and Dr. Mansi Shah, assistant professor in the Division of Thoracic Surgery, are leading this effort at the University of Kentucky. Their team is also the first in Kentucky — and among the first in the region — to perform thoracic procedures using the new single-port da Vinci robotic system, which allows complex operations through one small incision, helping patients recover faster and with less pain.  On this episode of 'Behind the Blue,' Drs. Meyerson and Shah explain how robotic technology is transforming lung-cancer care in Kentucky. They discuss the impact of same-day diagnosis and treatment, the benefits of single-port surgery for quicker recovery and reduced narcotic use, and the importance of encouraging more Kentuckians to take part in routine lung-cancer screening.  "Behind the Blue" is available via a variety of podcast providers, including iTunes and Spotify. Become a subscriber to receive new episodes of "Behind the Blue" each week. UK's latest medical breakthroughs, research, artists and writers will be featured, along with the most important news impacting the university.  "Behind the Blue" is a joint production of the University of Kentucky and UK HealthCare. Transcripts for most episodes are now embedded in the audio file and can be accessed in many podcast apps during playback. Transcripts for older episodes remain available on the show's blog page.  To discover how the University of Kentucky is advancing our Commonwealth, click here.

Host: Darryl S. Chutka, M.D. Guest: Daniel M. Frendl, M.D., Ph.D. If your practice includes middle age and older men, you've very likely diagnosed prostate cancer. It's the most diagnosed non-skin cancer in men in the U.S. Its incidence rises with age, with a median age of around 66 years. When found early, prostate cancer is very treatable, and in most cases, curable. Prostate specific antigen, or PSA is very effective in detecting early prostate cancer, but its use has been controversial due to the risk of overdiagnosis and overtreatment. What are the current recommendations for prostate cancer screening with PSA? What's the role of the digital rectal exam? How should we be using the PSA and what other tests are available for prostate cancer screening? The topic for this podcast is “Prostate Cancer Screening” and I'll be asking these questions to my guest, Daniel M. Frendl, M.D., Ph.D., a urologist at the Arizona campus of the Mayo Clinic. Tune in this Thursday for our next episode on "Prostate Cancer" releasing October 30, 2025. Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

Riverside Healthcare Imaging Patient Navigator Maureen Elliott discusses what to expect from a CT lung cancer screening and who should schedule an appointment.

SummaryIn this episode, Kimberly and Dr. Julianna Lindsey explore the interconnectedness of emotional and physical health, emphasizing the importance of stability in relationships and the impact of lifestyle choices on overall well-being. They discuss cardiovascular health, the significance of dietary choices, the effects of alcohol, and the role of supplements like glutathione and NAD in promoting longevity. The dialogue highlights the need for self-awareness and critical thinking in navigating health trends and misinformation.FATTY15OFFER: Fatty15 is on a mission to replenish your C15 levels and restore your long-term health. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/KIMBERLY and using code KIMBERLY at checkout.USE LINK: fatty15.com/KIMBERLYGLOWING GREENS POWDER OFFER: Go to mysolluna.com and use the CODE: PODFAM15 for 15% off your entire order. USE LINK: mysolluna.com CODE: PODFAM15 for 15% off your entire order. Chapters00:00 The Importance of Connection and Stability05:02 Understanding Cardiovascular Health and Screening10:05 Dietary Choices and Their Impact on Health14:54 The Role of Alcohol in Health and Wellness19:41 Exploring Supplements: Glutathione and NAD24:57 Navigating Health Trends and MisinformationSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

While we're making progress in TREATING cancer, worldwide cancer INCIDENCE is soaring, especially among young people; New guidelines for colon cancer screening urge earlier start at age 45; Rates of peanut allergy are declining as more parents follow revised advice to introduce nuts earlier to kids; What's with all the buzz about methylene blue? Legalization and stronger pot are creating an epidemic of ER visits for uncontrolled vomiting, debilitating abdominal pain; New smart toilet gives you a report card on your poop; When Zoloft doesn't work for anxiety.

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from October 18-24, 2025.

Send us a textGrab your trainers, your dog lead, and perhaps a pumpkin spice latte, and join us for some free CPD as we have another relaxed round up of recent Red Whale primary care Pearls of wisdom.  In the second of two episodes this month, Ali and Nik discuss: The NEW cervical screening intervals that apply in England from 1 July 2025: moving to a 5-yearly screening interval for all women and people with a cervix aged 25–64y who have tested negative for HPV and have no other risk factors (those living with HIV will be offered an annual screen). Varicella vaccination- this will finally be rolled out as part of the UK childhood vaccination schedule from 1 January 2026 – this is good news. What you might have missed is that guidance on post-exposure prophylaxis from the UKHSA has changed…wait for it…3 times in the past 2 years! We share our article on varicella and provide everything you need to know to decide whether post-exposure prophylaxis is needed. Listen as soon as you can to ensure you have full access to all the free resources. Cervical cancer screeningCancer Research UK - cervical cancer screening (more information about HPV triage and what the results mean)LGBT Health - smear leaflet (specific information leaflet for lesbian and bisexual women)OUTpatients – cancer risk and screeningOUTpatients – trans clinics offering cervical screeningVaricella UKHSA guidance on post exposure prophylaxis for chickenpox and shingles GP Trainee Essentials support package information, and the Red Whale Calendar for October 2025Send us your feedback podcast@redwhale.co.uk or send a voice message Sign up to receive Pearls here. Pearls are available for 3 months from publish date. After this, you can get access them plus 100s more articles when you buy a one-day online course from Red Whale OR sign up to Red Whale Unlimited. Find out more here. Follow us: X, Facebook, Instagram, LinkedInDisclaimer: We make every effort to ensure the information in this podcast is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in this podcast....

12:30pm - Brian Duff and Marty Biron talk to Dr. Mary Reed to talk about the importance of cancer screening

Lung cancer is the leading cause of cancer death in the United States for both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. This is because the disease shows no symptoms until it has progressed to advanced stages when it is very difficult to treat. The good news is that advances in imaging have made it possible to detect lung cancer early on, when treatment can be highly successful.The Eisenhower Lung Cancer Screening Program evaluates current and former smokers to determine their risk for lung cancer and provides assessment and evaluation for persons at risk for lung cancer.

Australia has its first new cancer screening programme in 20 years, this time for lung cancer. Today we'll be discussing this new programme in depth as well as the role of primary care and the supports available in delivering the programme.This podcast is Sponsored by the Australian Government National Lung Cancer Screening Program.Professor Vivienne Milch is Medical Director, at Cancer Australia. Professor Milch is also Medical Advisor to the Australian Commonwealth Department of Health, Disability and Ageing on cancer screening policy.Professor Milch holds a Master's degree in Health Policy and is an Adjunct Clinical Associate Professor in the School of Medicine, Sydney Campus at The University of Notre Dame, Australia and Professorial Fellow at the Caring Futures Institute at Flinders University in Adelaide. Prior to joining Cancer Australia, Professor Milch was a General Practitioner and clinical researcher at the Garvan Institute of Medical Research, Sydney. Relevant links: the Investigating Symptoms of Lung Cancer guide Healthcare Provider Toolkit The NLCSP website Program Guidelines GP guide resource Reducing stigma in the program Low-dose CT Scan request form eLearning modules developed by Lung Foundation Australia Actionable additional findings guidelines

Research shows breast cancer is the second leading cause of cancer death in women in the U.S. Data also reveals that in a group of eight women, one will be diagnosed with breast cancer. Additionally, there’s been a growing increase in the number of younger women being diagnosed with breast cancer. According to the Centers for Disease Control and Prevention, at least 27,136 women under the age of 45 were diagnosed with breast cancer in 2022. October marks National Breast Cancer Awareness Month. On Thursday’s edition of “Closer Look,” program host Rose Scott talks with guests about everything from diagnosis to treatment, as well as the importance of younger women participating in clinical research trials. Guests included: Ashley Kennedy, a breast cancer survivor and participant of the 2025 Komen Georgia MORE THAN PINK Walk Theru Ross, the senior program manager of community outreach at Susan G. Komen Dr. Joel Okoli, a professor of surgery in the division of Surgical Oncology at Morehouse School of Medicine Plus, it's the end of an era. EATS, which is regarded as a neighborhood cafeteria, is closing after nearly 33 years. We hear from Robert "Bob" Hatcher, the owner of the eatery known for its meat-and-three format. He reflects on the day the restaurant opened and thanked his customers for making the restaurant part of the community.See omnystudio.com/listener for privacy information.

Smoking rates are high in rural parts of Ohio, but screening for lung cancer there can be hard to come by. A new mobile unit aims to help.

Greetings Humor Consumers! In this powerful yet hilariously honest episode, Tracy and Cathrine dive into cancer screenings and early detection—a topic most people avoid, ignore, or delay. Tracy opens with her personal breast cancer survival story involving an oncologist, radiation, and a possible perk: a higher, tighter boob.

“Too many women skip mammograms because of pain. But now, there's another option.” — Dr. Margaret Nachtigall  Key Links & Resources  Learn more about Pink Medical and VeraScan HERE   Follow Barbara on Instagram HERE    Contact Barbara: agebetterpodcast@gmail.com  About This Episode  In this episode of AGE BETTER, Barbara is joined by frequent guest Dr. Margaret Nachtigall, reproductive endocrinologist at NYU and Medical Director of Pink Medical. Together, they discuss why mammograms are essential for early detection, why pain has been a barrier for too many women, and how new technology like VeraScan is changing the future of breast cancer screening. They also dive into how hormonal changes affect breast density, the role of genetic testing, and what women of all ages can do to stay proactive about breast health.  Why You Should Listen  Understand why breast cancer screening is still the number one tool for early detection and survival.  Learn how VeraScan offers a painless, compression-free alternative to traditional mammograms.  Discover how hormonal changes — especially around menopause — impact breast density and screening needs.  Hear how genetic testing is being used to personalize breast health care.  Walk away with practical strategies and Dr. Margaret's top takeaways for staying on top of your breast health.  If you're enjoying Age Better, I'd be so grateful if you left a quick review wherever you listen.       And if there's a topic or question you'd love for me to cover in a future episode, send a note to agebetterpodcast@gmail.com -- I love hearing from you!     Learn more about your ad choices. Visit megaphone.fm/adchoices

Read the full show notes on Dr. Aimee's website. Dr. Aimee invites board-certified genetic counselor Natalie Richeimer to discuss the crucial intersection of genetic counseling, IVF, and cancer. Natalie explains the role of genetic counselors in the fertility space, particularly how they assist patients in understanding their risk for genetic conditions stemming from family history, personal health, or ethnicity. Dr. Aimee and Natalie talk about the important work done by JScreen, an organization providing accessible genetic testing for cancer and carrier screening. The conversation highlights the importance of understanding whether cancer is hereditary or sporadic, the implications of genetic predispositions, and how early genetic testing can impact fertility planning and treatment options. Natalie shares insights on the different types of genetic tests available, including those for embryos, and emphasizes the evolving nature and expanding role of genetic testing in family planning. They also discuss common misconceptions about genetic testing, especially among patients with a family history of cancer, and offer practical advice on how to access genetic counseling and testing through JScreen. Read the the full article on Dr. Aimee's site.  JScreen's website JScreen on Instagram Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, October 20, 2025 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Mississippi lawmakers are hearing why genetic testing for cancer patients could give them better access to more effective treatment.Then: New guidelines released this week from the CDC now determine who can get and give the COVID vaccine. Plus: how college students are being prepared to work alongside artificial intelligence. Hosted on Acast. See acast.com/privacy for more information.

RNA is easier to detect and points toward cancer activity better than DNA testing, a recent study concludes. Johns Hopkins Kimmel Cancer Center director William Nelson says there's an even more accurate method on the horizon. Nelson: Will RNA sequencing … Will RNA based tests form the basis for cancer screening and monitoring? Elizabeth Tracey reports Read More »

Nurse practitioner Elisabeth Evans discusses her article "The critical role of nurse practitioners in colorectal cancer screening." Elisabeth shares why colorectal cancer is the second-deadliest cancer in the U.S. yet remains under-screened, and why early detection can mean the difference between a 14 percent survival rate and over 90 percent. She highlights the lowered screening age, the role of public figures in raising awareness, and how nurse practitioners and physician associates can normalize conversations, provide multiple screening options, and ease patient fears. Elisabeth also discusses environmental risk factors, the importance of family history, and the potential of emerging technologies like blood-based screening. Listeners will take away strategies to better support patients, improve screening rates, and save lives through prevention and timely intervention. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

In this episode of Confessions of a Male Gynecologist, Dr. Shawn Tassone explores the vital connection between hormone health and breast cancer screening. Drawing from his best-selling book The Hormone Balance Bible, he breaks down the most common screening methods — mammography, ultrasound, and thermography — and explains how each one works, their benefits, and their limitations. Dr. Tassone also discusses emerging imaging technologies, like the QT scan, and emphasizes why understanding your options is key to prevention and peace of mind. Whether you're curious about alternative testing methods or looking to make informed choices about your breast health, this episode empowers women with knowledge to take charge of their own care. Episode Highlights: Key takeaways from The Hormone Balance Bible on hormone imbalances and overall wellness The differences between mammography, ultrasound, and thermography in breast cancer screening Why thermography is a physiological test, while mammography and ultrasound focus on structure The pros and cons of each screening method — and why no single test is perfect How ultrasound can sometimes catch what mammograms miss The lower false-positive rate associated with thermography The promise of emerging imaging technologies like the QT scan Why prevention is more powerful than detection in the fight against cancer How to choose the breast screening method that aligns best with your health goals and comfort level Episode Resources: Dr. Shawn Tassone's Practice | Tassone Advanced Gynecology Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormonal Archetype Quiz Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

Learn more behind the meaning of the Grab & Go® to Give campaign and the incredible nonprofits we're partnering with to show support for those impacted by breast cancer - https://www.standleeforage.com/promotions/grab-go-give/ On this episode, host Katy Starr chats with Jane Beshear, former First Lady of Kentucky and founder of Horses and Hope, about how she turned a lifelong love of horses into a movement that brings breast cancer education and mobile screenings to medically underserved individuals in the horse industry, including: How Horses and Hope began and why they focused on racetracks and backside of the track The impact of fundraising $1 million for a mobile cancer screening van that now provides thousands of mammograms and cancer screenings all across KentuckyPractical steps every listener can take for early detectionPlus, we talk about her equestrian background, the important role horses have played in her life, and how connecting with survivors at the Horses and Hope hosted events has changed her life.

October marks Breast Cancer Awareness Month. We are providing 2025 update for our 3 part breast cancer episodes, in part 1 today we cover an introduction on breast cancer screening, prevention. 

This week Bobbi Conner talks with MUSC's Dr. Eric Wallen about prostate cancer screening.

Original Air Date: 10-18-2024Host: Jasmine T. Kency, M.D., Associate Professor of Internal Medicine and Pediatrics at the University of Mississippi Medical Center.Topic: New Clinical Developments - Recommended Colonoscopies, Cancer Screenings, Aspirin Intake, and MoreEmail the show: remedy@mpbonline.org. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

In this Healthed lecture, the experts will answer questions about changes to the prostate cancer screening guidelines including the updated risk: benefit profile for PSA testing, who should have this test and how PSA test results should now be interpreted and managed. In addition, this case-based discussion will cover the practical application of the new draft guidelines on prostate cancer screening that are likely to be endorsed and become standard of care in the near future.See omnystudio.com/listener for privacy information.

Half of Americans skipped important cancer screenings in the past year. How does fear play a major factor? Or the amount of time we have? We spoke with Christopher Scuderi, DO, a primary-care physician and cancer survivor, about which screenings are most often missed, the risks of delaying them, screening guidelines to be aware of, and how to prioritize our health despite fear of knowing or busy schedules. He also highlights how talking with your doctor can help identify personal risk factors and the role healthy habits – like diet, exercise, sleep, and stress management – play in lowering cancer risk and supporting overall well-being.See omnystudio.com/listener for privacy information.

Lung cancer is one of the world's biggest killers. Today, we explore why, and how medical research into this disease is seeing the development of better diagnostic tools, cancer treatments and even a vaccine to prevent tumours from taking hold in the first place... Like this podcast? Please help us by supporting the Naked Scientists

340B savings do not just enable hospitals to provide more care, they also help hospitals pioneer innovative approaches to bringing care directly to patients. For West Virginia University Medicine, which serves a high population of Medicare and Medicaid patients, one of these 340B-funded innovations came from recognizing a need to increase cancer screening rates. WVU Medicine 340B Enterprise Director Karen Famoso tells us how the system's mobile cancer screening initiative came about.The Barriers to Cancer ScreeningWVU Medicine identified that some of the biggest social determinants of health for its West Virginia patients were relatively unique to the areas it serves. The rural state has significant travel barriers, small population areas, and high poverty rates, a combination that leaves thousands of patients without easy access to a source of primary care.Mobile Screenings Look for Breast, Lung CancersToday, WVU Medicine operates two types of mobile cancer projects: Bonnie's Bus and LUCAS. The former launched in 2009 and is a mobile mammography unit named after a patient who died because she had limited access to breast cancer screenings. Her family donated funding to the hospital to support this effort. More than a decade later, WVU Medicine introduced the mobile lung screening program LUCAS. That initiative provides low-dose CT scans to patients meeting the screening guideline using a nearly 70,000-pound tractor trailer.340B Is Key To Sustaining Mobile Screening EffortsFamoso says WVU Medicine funds its mobile cancer screening programs through grants and donations, but that is not enough to cover the full cost. That is where 340B savings can help cover the operating loss, which was almost $400,000 last year. Without those 340B savings, the health system's financial situation would not allow investments in mission-focused programs such as Bonnie's Bus and LUCAS.ResourcesLung Cancer Screening on WheelsHRSA Reviewing Rebate Pilot Proposals and CommentsSecond Federal Appeals Court Upholds State Contract Pharmacy Law

Send us a message with this link, we would love to hear from you. Standard message rates may apply.Colon cancer screening saves lives by catching cancer early and even preventing it, yet only 69% of eligible adults are up to date with their screenings. We explore who needs screening, what tests are available, and how to choose the right one for you.• Most adults should start colon cancer screening at age 45, even if healthy• Family history may mean you need to start screening earlier• Stool-based tests like FIT and Cologuard are convenient home options• Colonoscopy remains the gold standard, allowing doctors to remove polyps• One in 23 men and one in 25 women will develop colorectal cancer• The best screening test is the one you'll actually completePlease get screened! Check with your doctor about which test is right for you based on your risk factors and preferences.References1. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians (Version 2). Qaseem A, Harrod CS, Crandall CJ, et al. Annals of Internal Medicine. 2023;176(8):1092-1100. doi:10.7326/M23-0779.2. AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review. Issaka RB, Chan AT, Gupta S. Gastroenterology. 2023;165(5):1280-1291. doi:10.1053/j.gastro.2023.06.033.3. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Davidson KW, Barry MJ, Mangione CM, et al. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238.4. Colorectal Cancer Screening and Prevention. Sur DKC, Brown PC. American Family Physician. 2025;112(3):278-283.5. Increasing Incidence of Early-Onset Colorectal Cancer. Sinicrope FA. The New England Journal of Medicine. 2022;386(16):1547-1558. doi:10.1056/NEJMra2200869.6. From Guideline to Practice: New Shared Decision-Making Tools for Colorectal Cancer Screening From the American Cancer Society. Volk RJ, Leal VB, Jacobs LE, et al. CA: A Cancer Journal for Clinicians. 2018;68(4):246-249. doi:10.3322/caac.21459.7. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. JAMA. 2021;325(19):1978-1998. doi:10.1001/jama.2021.4417.8. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989.9. How Would You Screen This Patient for Colorectal Cancer? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Burns RB, Mangione CM, Weinberg DS, Kanjee Z. Annals of Internal Medicine. 2022;175(10):1452-1461. doi:10.7326/M22-1961.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Prostate cancer is one of the most urgent health issues facing men in Pennsylvania, according to cancer advocates and survivors who are working to remove barriers to early detection.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Thoracic radiologists Jeffrey Kanne, Miranda Siemienowicz and Jonathan Chung discuss the current global status of lung cancer screening, offering tips and tricks for reading these studies. Meanwhile, Andrew and Frank talk about everything BUT pulmonary nodules: another shameful journal travesty, TB sniffer rats and ketamine epiphanies.   Lung cancer screening article ► https://radiopaedia.org/articles/lung-cancer-screening Retraction Watch - Tin Man Syndrome ► https://retractionwatch.com/2025/08/15/tin-man-syndrome-case-plagiarized-from-hoax-sleuths-say/ Those TB detecting rats ► https://apopo.org/what-we-do/detecting-tuberculosis Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents.